Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gemin X has said its compound that treats acute lymphoblastic leukemia produced positive results in a recent study.
Subscribe to our email newsletter
According to the study, GX15-070 demonstrated potent single agent activity against acute lymphoblastic leukemia (ALL) blast cells, and also enhanced chemosensitivity and was synergistic with cytotoxic drugs. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.
“GX15-070 is an appropriate candidate for ALL treatment because the imbalanced expression of Bcl-2 family proteins in this cancer leads to impaired apoptosis,” said Gordon Shore, chief scientific officer of Gemin X.
“Additionally this study further upholds what we already have observed about our lead candidate’s utility as a single agent and in combination with other therapies.”
Gemin X is currently conducting several clinical trials of GX15-070 in multiple cancer types as a combination therapy and as a single agent. In phase I studies, GX15-070 was well-tolerated and resulted in clinical and biological activity.